CNS Pharmaceuticals, Inc. (CNSP) — SEC Filings

Latest SEC filings for CNS Pharmaceuticals, Inc. (CNSP), explained in plain English.

Sentiment Overview: 1 bullish, 4 bearish, 44 neutral, 1 mixed

Recent Filings (50)

• CNS Pharmaceuticals Files 8-K on Officer Changes and Financials — 8-K · 2025-12-17T00:00:00.000Z [neutral] Risk: medium
  On December 16, 2025, CNS Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive officers. The filing also includes
• 8-K Filing — 8-K · 2025-11-21T00:00:00.000Z [neutral]
• CNSP Narrows Q3 Loss Amidst Aggressive Equity Raises — 10-Q · 2025-11-14T00:00:00.000Z [bearish] Risk: high
  CNS Pharmaceuticals, Inc. (CNSP) reported a net loss of $9,894,762 for the nine months ended September 30, 2025, an improvement from the $11,681,435 net loss in
• DEFA14A Filing — DEFA14A · 2025-11-12T00:00:00.000Z [neutral]
• CNS Pharma Seeks Massive Share Increase, Signaling Potential Dilution — DEF 14A · 2025-10-24T00:00:00.000Z [bearish] Risk: high
  CNS Pharmaceuticals, Inc. (CNSP) is holding its Annual Meeting of Stockholders on November 17, 2025, virtually, to address several critical proposals. The compa
• CNS Pharma's Cash Boosted by Offerings Amid Rising R&D, Mounting Losses — 10-Q · 2025-08-14T00:00:00.000Z [mixed] Risk: high
  CNS Pharmaceuticals, Inc. reported a net loss of $6,676,281 for the six months ended June 30, 2025, an increase from the $6,075,501 net loss in the same period
• CNS Pharmaceuticals Closes $1.5M Private Placement — 8-K · 2025-07-22T00:00:00.000Z [neutral] Risk: medium
  On July 17, 2025, CNS Pharmaceuticals, Inc. filed an 8-K report detailing several key events. The company announced the closing of a private placement of its co
• CNS Pharmaceuticals Files 8-K Report — 8-K · 2025-07-15T00:00:00.000Z [neutral] Risk: low
  On July 15, 2025, CNS Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. N
• CNS Pharmaceuticals Files Q1 2025 10-Q — 10-Q · 2025-05-15T00:00:00.000Z [neutral] Risk: medium
  CNS Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business o
• CNS Pharmaceuticals Files S-1/A Amendment — S-1/A · 2025-05-12T00:00:00.000Z [neutral] Risk: medium
  CNS Pharmaceuticals, Inc. filed an S-1/A amendment on May 12, 2025, for its registration statement. The company, incorporated in Nevada, is in the pharmaceutica
• CNS Pharmaceuticals Files 10-K/A Amendment — 10-K/A · 2025-04-30T00:00:00.000Z [neutral] Risk: medium
  CNS Pharmaceuticals, Inc. filed an amendment (10-K/A) on April 30, 2025, to its annual report for the fiscal year ended December 31, 2024. This amendment specif
• CNS Pharmaceuticals Files S-1 with SEC — S-1 · 2025-04-14T00:00:00.000Z [neutral] Risk: medium
  CNS Pharmaceuticals, Inc. filed an S-1 registration statement with the SEC on April 14, 2025. The company, incorporated in Nevada, is in the pharmaceutical prep
• CNS Pharmaceuticals Files 8-K Report — 8-K · 2025-04-09T00:00:00.000Z [neutral] Risk: low
  On April 9, 2025, CNS Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 2100 West Loop So
• CNS Pharmaceuticals Files 2024 10-K — 10-K · 2025-03-31T00:00:00.000Z [neutral] Risk: medium
  CNS Pharmaceuticals, Inc. filed its 2024 10-K on March 31, 2025, reporting on its fiscal year ending December 31, 2024. The company, incorporated in Nevada and
• CNS Pharmaceuticals Files 8-K: Other Events & Financials — 8-K · 2025-03-20T00:00:00.000Z [neutral] Risk: low
  On March 20, 2025, CNS Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicati
• CNS Pharmaceuticals Files 8-K: Security Holder Rights & Exhibits — 8-K · 2025-02-21T00:00:00.000Z [neutral] Risk: low
  On February 19, 2025, CNS Pharmaceuticals, Inc. filed an 8-K report detailing material modifications to security holder rights and other events. The filing also
• CNS Pharmaceuticals Closes $1.5M Private Placement — 8-K · 2025-01-03T00:00:00.000Z [neutral] Risk: medium
  On January 3, 2025, CNS Pharmaceuticals, Inc. filed an 8-K report detailing several events. The company announced the closing of a private placement of its comm
• CNS Pharmaceuticals Files Current Report — 8-K · 2024-12-11T00:00:00.000Z [neutral] Risk: low
  On December 11, 2024, CNS Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's current report status and financial statements
• CNS Pharmaceuticals Files 8-K on Shareholder Vote Matters — 8-K · 2024-12-03T00:00:00.000Z [neutral] Risk: low
  On November 26, 2024, CNS Pharmaceuticals, Inc. filed an 8-K report to disclose matters submitted to a vote of its security holders. The filing indicates a shar
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• CNS Pharmaceuticals Files Q3 2024 10-Q — 10-Q · 2024-11-14T00:00:00.000Z [neutral] Risk: medium
  CNS Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the third quarter and the first ni
• CNS Pharmaceuticals Appoints New Chief Medical Officer — 8-K · 2024-11-01T00:00:00.000Z [neutral] Risk: medium
  On October 30, 2024, CNS Pharmaceuticals, Inc. announced the appointment of Dr. John "Jack" W. Smith as Chief Medical Officer. Dr. Smith brings extensive experi
• CNS Pharmaceuticals Files Definitive Proxy Statement — DEF 14A · 2024-10-28T00:00:00.000Z [neutral] Risk: low
  CNS Pharmaceuticals, Inc. filed its definitive proxy statement on October 28, 2024, for its annual meeting of stockholders. The filing outlines the proposals to
• CNS Pharmaceuticals Files 8-K for Material Definitive Agreement — 8-K · 2024-10-24T00:00:00.000Z [neutral] Risk: medium
  On October 23, 2024, CNS Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The company, incorporated in Nevada with its principal executive of
• CNS Pharmaceuticals Files 8-K — 8-K · 2024-10-23T00:00:00.000Z [neutral] Risk: low
  On October 23, 2024, CNS Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 2100 West Loop
• CNS Pharmaceuticals Faces Nasdaq Listing Rule Non-Compliance — 8-K · 2024-09-18T00:00:00.000Z [neutral] Risk: high
  CNS Pharmaceuticals, Inc. received a notification on September 12, 2024, indicating it failed to meet a continued listing rule or standard for the Nasdaq Capita
• CNS Pharmaceuticals Faces Delisting Notice — 8-K · 2024-09-12T00:00:00.000Z [bearish] Risk: high
  CNS Pharmaceuticals, Inc. filed an 8-K on September 10, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is bas
• CNS Pharmaceuticals Files Q2 2024 10-Q — 10-Q · 2024-08-14T00:00:00.000Z [neutral] Risk: medium
  CNS Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results for the second quarter and the first ha
• CNS Pharmaceuticals Appoints New Chief Medical Officer — 8-K · 2024-08-07T00:00:00.000Z [neutral] Risk: medium
  On August 6, 2024, CNS Pharmaceuticals, Inc. announced the appointment of Dr. John A. McCarthy as Chief Medical Officer. Dr. McCarthy brings extensive experienc
• Cortice Biosciences Files 13D for CNS Pharmaceuticals — SC 13D · 2024-08-02T00:00:00.000Z [neutral] Risk: medium
  Cortice Biosciences, Inc. has filed a Schedule 13D on August 2, 2024, indicating a change in beneficial ownership of CNS Pharmaceuticals, Inc. common stock. The
• CNS Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — 8-K · 2024-07-30T00:00:00.000Z [neutral] Risk: medium
  On July 29, 2024, CNS Pharmaceuticals, Inc. entered into a material definitive agreement, likely related to its operations in the pharmaceutical preparations in
• CNS Pharmaceuticals Files Material Definitive Agreement — 8-K · 2024-07-26T00:00:00.000Z [neutral] Risk: medium
  On July 26, 2024, CNS Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements and exh
• CNS Pharmaceuticals Faces Nasdaq Delisting Warning — 8-K · 2024-07-24T00:00:00.000Z [bearish] Risk: high
  CNS Pharmaceuticals, Inc. received a notice on July 19, 2024, indicating it failed to meet the minimum bid price requirement for continued listing on the Nasdaq
• CNS Pharmaceuticals Files S-1/A Amendment — S-1/A · 2024-07-19T00:00:00.000Z [neutral] Risk: medium
  CNS Pharmaceuticals, Inc. filed an S-1/A amendment on July 19, 2024, to update its registration statement. The company, incorporated in Nevada with its principa
• CNS Pharmaceuticals Files S-1 for Public Offering — S-1 · 2024-07-12T00:00:00.000Z [neutral] Risk: medium
  CNS Pharmaceuticals, Inc. filed an S-1 registration statement on July 12, 2024, indicating plans to offer securities. The company, incorporated in Nevada with p
• CNS Pharmaceuticals Appoints New Chief Medical Officer — 8-K · 2024-07-09T00:00:00.000Z [neutral] Risk: medium
  On July 5, 2024, CNS Pharmaceuticals, Inc. announced the appointment of Dr. John W. Semple as Chief Medical Officer. Dr. Semple brings extensive experience in n
• CNS Pharmaceuticals Raises $1M in Stock Sale — 8-K · 2024-07-03T00:00:00.000Z [neutral] Risk: medium
  On July 3, 2024, CNS Pharmaceuticals, Inc. announced an entry into a material definitive agreement, specifically a Securities Purchase Agreement with an accredi
• SC 13G Filing — SC 13G · 2024-07-02T00:00:00.000Z [neutral]
• CNS Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — 8-K · 2024-06-26T00:00:00.000Z [neutral] Risk: medium
  On June 26, 2024, CNS Pharmaceuticals, Inc. announced an entry into a material definitive agreement. The company also reported on unregistered sales of equity s
• SC 13G Filing — SC 13G · 2024-06-25T00:00:00.000Z [neutral]
• CNS Pharmaceuticals Files 8-K Amendment — 8-K/A · 2024-06-20T00:00:00.000Z [neutral] Risk: low
  CNS Pharmaceuticals, Inc. filed an amendment (8-K/A) on June 20, 2024, to its current report originally filed on June 14, 2024. This amendment primarily concern
• CNS Pharmaceuticals Closes $1.5M Stock Sale — 8-K · 2024-06-14T00:00:00.000Z [neutral] Risk: medium
  On June 14, 2024, CNS Pharmaceuticals, Inc. entered into a Material Definitive Agreement, specifically a Securities Purchase Agreement, with an investor. This a
• CNS Pharmaceuticals Files S-1 for Future Offering — S-1 · 2024-06-10T00:00:00.000Z [neutral] Risk: medium
  CNS Pharmaceuticals, Inc. filed an S-1 registration statement on June 7, 2024, for an unspecified offering. The company, incorporated in Nevada with its princip
• CNS Pharmaceuticals Closes $1.5M Private Placement — 8-K · 2024-06-05T00:00:00.000Z [bullish] Risk: medium
  On June 3, 2024, CNS Pharmaceuticals, Inc. filed an 8-K report detailing several key events. The company announced the closing of a private placement of its com
• CNS Pharmaceuticals Files 8-K — 8-K · 2024-05-16T00:00:00.000Z [neutral] Risk: low
  CNS Pharmaceuticals, Inc. filed an 8-K on May 16, 2024, to report on its results of operations and financial condition, as well as to file financial statements
• CNS Pharmaceuticals Files 10-Q for Period Ending March 31, 2024 — 10-Q · 2024-05-15T00:00:00.000Z [neutral] Risk: medium
  CNS Pharmaceuticals, Inc. (CNSP) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. CNS Pharmaceuticals, Inc. filed a 10-Q for the quarter ended Marc
• CNS Pharmaceuticals Appoints New Chief Medical Officer — 8-K · 2024-05-07T00:00:00.000Z [neutral] Risk: medium
  On May 6, 2024, CNS Pharmaceuticals, Inc. announced the appointment of Dr. John M. McCarthy as Chief Medical Officer. Dr. McCarthy brings extensive experience i
• CNS Pharmaceuticals Announces Board Changes and Officer Appointments — 8-K · 2024-05-03T00:00:00.000Z [neutral] Risk: medium
  On April 30, 2024, CNS Pharmaceuticals, Inc. filed an 8-K report detailing several key events. These include the election of Dr. John "Jack" Roberts as Chairman
• CNS Pharmaceuticals Files 8-K — 8-K · 2024-04-15T00:00:00.000Z [neutral] Risk: low
  On April 9, 2024, CNS Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with a Regulation FD dis
• CNS Pharmaceuticals, Inc. Announces 2024 Annual Meeting of Stockholders on April 30 — DEF 14A · 2024-04-10T00:00:00.000Z [neutral] Risk: low
  CNS Pharmaceuticals, Inc. (CNSP) filed a Proxy Statement (DEF 14A) with the SEC on April 10, 2024. The 2024 Annual Meeting of Stockholders for CNS Pharmaceutica